We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Complementary Biomolecular Analysis Instruments Available for Research and Clinical Labs

By LabMedica International staff writers
Posted on 31 Mar 2014
Two new instruments for biomolecular analysis feature coated sensor chips (microarray format and mini format respectively) and assay protocols ready to support almost any research and development application from kinetic evaluation of microarrays to online immobilization.

The instruments—b-screen and b-portable—are products of Biametrics GmbH (Tübingen, Germany). More...
Biametrics develops and markets label-free analytical system solutions for life science applications.

Biametrics has recently launched two new product lines intended to facilitate research in diverse types of life science laboratories. The b-screen device is able to handle any standard microarray format and can detect up to 10,000 bimolecular interactions in a single measurement. The b-portable device enables high quality label-free interaction analysis under laboratory or field conditions using a smart and inexpensive technology platform.

Current applications for b-screen include bioanalytics, drug discovery, production, and quality control. Based on the same technology, b-portable is a point-of-care device for early cancer and infection detection.

The b-screen instrument provides label-free read-out of up to 10,000 spots per square centimeter. It utilizes a precise and automated microfluidics system for incubation of the microarray with the sample of interest. The instrument can be used with multiple array layouts, uses glass or plastic type substrates, and is compatible with almost any common microarray printer. No fluorescence labels are needed, which leads to assay conditions similar to the in -vivo situation combined with minimal sample pretreatment and minimized reagent consumption.

Both b-screen and b-portable may be used with different sample types such as serum or whole blood or other relevant complex matrices such as cell culture medium. Kinetic data can be obtained for almost any kind of biomolecular interaction such as those between proteins, between peptides and proteins, and between small molecules and proteins.

“With b-screen users are able to easily transfer existing microarrays directly into a label-free assay format thus gaining additional information on kinetics and thermodynamics at high precision and reliability,” said Günther Proll, managing director of Biametrics. “The device allows very low cost high-throughput screening and the applications we have established demonstrate excellent performance and outcome characteristics. We believe b-screen provides key advantages over current options like surface plasmon resonance (SPR).”

Related Links:

Biametrics GmbH



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.